RhumbLine Advisers
TSHA icon

RhumbLine Advisers’s Taysha Gene Therapies TSHA Stock Holding History

RhumbLine Advisers’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.04M Buy
299,975
+41,445
+16% +$245K ﹤0.01% 1924
2026
Q1 		$1.16M Buy
258,530
+1,090
+0.4% +$5.07K ﹤0.01% 2123
2025
Q4 		$1.42M Sell
257,440
-31,419
-11% -$153K ﹤0.01% 2052
2025
Q3 		$945K Buy
288,859
+55,603
+24% +$157K ﹤0.01% 2275
2025
Q2 		$539K Buy
233,256
+27,794
+14% +$60.4K ﹤0.01% 2643
2025
Q1 		$286K Buy
205,462
+13,383
+7% +$22.4K ﹤0.01% 2917
2024
Q4 		$332K Buy
192,079
+5,831
+3% +$12.1K ﹤0.01% 2931
2024
Q3 		$374K Buy
186,248
+1,964
+1% +$4.31K ﹤0.01% 2900
2024
Q2 		$413K Buy
+184,284
New +$536K ﹤0.01% 2809
2022
Q2 		– Sell
-22,389
Closed -$146K – 3237
2022
Q1 		$146K Buy
22,389
+2,619
+13% +$19.6K ﹤0.01% 2825
2021
Q4 		$230K Sell
19,770
-361
-2% -$5.45K ﹤0.01% 2796
2021
Q3 		$375K Buy
20,131
+1,460
+8% +$27.8K ﹤0.01% 2678
2021
Q2 		$396K Buy
+18,671
New +$430K ﹤0.01% 2663

Other funds holding TSHA

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vestal Point Capital
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RhumbLine Advisers's TSHA Position: Q2 2026 in Review

RhumbLine Advisers increased its Taysha Gene Therapies (TSHA) stake by 16% in Q2 2026, buying an estimated $245K and bringing the position to 299,975 shares worth $2.04M. The position accounts for ﹤0.01% of the portfolio, ranked #1924.

RhumbLine Advisers first reported a position in TSHA in Q2 2021 and has held it in 13 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • RhumbLine Advisers held 299,975 shares of Taysha Gene Therapies worth $2.04M as of Q2 2026.
  • RhumbLine Advisers bought 41,445 Taysha Gene Therapies shares in Q2 2026, an estimated $245K.
  • Taysha Gene Therapies made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1924 holding.
  • RhumbLine Advisers first reported a position in Taysha Gene Therapies in Q2 2021 and has held it in 13 quarters since.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.